Experimental Treatment for Patients with Open Angle Glaucoma
common.study.values.description
“Long-term Safety and Efficacy Extension Trial of Bimatoprost SR”
This study will evaluate the long-term safety and efficacy of Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Bimatoprost SR
Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye. Fellow eye of all patients will receive only standard of care based on the investigator's judgment
participant.views.study.view.additional
participant.views.study.view.scientific-title
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension
common.study.values.clinical-trial-id
NCT03891446
participant.views.study.view.id
aKrBJe
